nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

Open Access 14.02.2023 | Invited Review

Arketamine for cognitive impairment in psychiatric disorders

verfasst von: Kenji Hashimoto

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 7/2023

Abstract

Cognitive impairment has been observed in patients with various psychiatric disorders, including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BD). Although modern therapeutic drugs can improve certain symptoms (i.e., psychosis, depression) in these patients, these drugs have not been found to improve cognitive impairment. The N-methyl-D-aspartate receptor antagonist (R,S)-ketamine has attracted attention as a rapidly acting antidepressant. In addition to its robust antidepressant effects, (R,S)-ketamine has been suggested to improve cognitive impairment in patients with MDD and BD, despite causing cognitive impairment in healthy control subjects. (R,S)-ketamine is a racemic mixture of equal amounts of (R)-ketamine (or arketamine) and (S)-ketamine (or esketamine). Arketamine has been found to have more potent antidepressant-like actions than esketamine in rodents. Interestingly, arketamine, but not esketamine, has been suggested to improve phencyclidine-induced cognitive deficits in mice. Furthermore, arketamine has been suggested to ameliorate cognitive deficits in rodent offspring after maternal immune activation. In the current article, it is proposed that arketamine has therapeutic potential for treating cognitive impairment in patients with psychiatric disorders. Additionally, the potential role of the gut–microbiome–brain axis in cognitive impairment in psychiatric disorders is discussed.

Introduction

Cognitive impairment is common in patients with various psychiatric disorders, including schizophrenia, major depressive disorder (MDD), bipolar disorder (BD), autism spectrum disorder (ASD), post-traumatic stress disorder (PTSD), attention deficit/hyperactivity disorder (ADHD), obsessive–compulsive disorder (OCD), panic disorder, generalized anxiety disorder, and social anxiety disorder (Fig. 1) [1‐3]. Several batteries, such as the Brief Assessment of Cognition in Schizophrenia (BACS), MATRICS Consensus Cognitive Battery (MCCB), Cambridge Neuropsychological Test Automated Battery (CANTAB), the Cogstate battery, and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) have been used to measure cognitive function in humans. Using the Cogstate battery, we previously reported that cognitive impairment in patients with schizophrenia was more severe than that in patients with MDD [4, 5]. The affected cognitive domains in patients with schizophrenia include memory, attention/concentration, problem solving, learning, executive function, processing speed, and social cognition. Furthermore, declines of these cognitive functions impact various domains, such as activities of daily living, occupational functioning, social functioning, relationships, health-related quality of life and adherence to treatment, resulting in increased direct and indirect costs associated with the treatment of schizophrenia (Fig. 2) [6]. A recent systematic review showed cognitive deficits in patients with MDD in the acute and remitted state [3]. Cognitive impairment of psychiatric disorders is not just a secondary consequence of perturbed affect, despite a close relationship between cognition and psychiatric symptoms. Although certain symptoms (i.e., psychosis, depression, anxiety) in patients with psychiatric disorders could be alleviated by the current therapeutic drugs, these drugs could not improve cognitive impairment [1]. Therefore, the development of novel therapeutic drugs for cognitive impairment is an unmet need [7‐9].

Glutamatergic neurotransmission via the N-methyl-D-aspartate receptor (NMDAR) regulates synaptic plasticity, memory, and cognition. Abnormalities in glutamatergic neurotransmission via the NMDAR play a role in cognitive impairment of psychiatric disorders (Fig. 3). In addition to psychomimetic and dissociative symptoms, NMDAR antagonists such as phencyclidine (PCP) and (R,S)-ketamine are known to cause cognitive impairment in rodents and humans [10‐18]. There are several reports showing abnormalities in NMDAR-mediated amino acids (i.e., D-serine and L-serine) in patients with schizophrenia [19‐22]. Recent mega-analysis of proton magnetic resonance spectroscopy (MRS) shows altered levels of glutamate in the brain from patients with schizophrenia [23]. Furthermore, abnormalities in NMDAR-mediated neurotransmission are implicated in mood disorders such as MDD and BD [24‐29]. Meta-analyses of MRS studies showed altered levels of glutamate in the brain from patients with MDD or BD [30, 31]. Interestingly, there were significant correlations between cognitive functions and glutamate levels in the brain from first episode drug-naïve patients with MDD [32]. Collectively, it is likely that abnormalities in glutamatergic neurotransmission might play a role in the cognitive impairment in patients with psychiatric disorders (Fig. 3). Taken all together, previous research suggests that NMDAR could be a therapeutic target for cognitive impairment in patients with psychiatric disorders [14, 18, 33, 34].

It is widely recognized that (R,S)-ketamine causes cognitive impairment in healthy subjects [12, 13, 35]. However, increasing evidence suggests that (R,S)-ketamine may improve cognitive impairment in patients with mood disorders such as MDD and BD [36, 37]. In the current article, the author reviewed the therapeutic potential of (R,S)-ketamine and its enantiomer (R)-ketamine (or arketamine) for cognitive impairment in neuropsychiatric disorders. Furthermore, the author discussed the possible role of the gut–microbiota–brain axis in cognitive impairment of psychiatric disorders.

Brief history of (R,S)-ketamine and its enantiomers

In 1962, (R,S)-ketamine was synthesized as an alternative short-acting anesthetic of PCP [38]. In 1970, (R,S)-ketamine was approved for use as an anesthetic in the United States of America (USA). In 1985, (R,S)-ketamine was included on the World Health Organization’s List of Essential Medicines [39]. (R,S)-ketamine is a racemic mixture of equal amounts of (R)-ketamine (or arketamine) and (S)-ketamine (or esketamine). Esketamine has greater affinity for the NMDAR than arketamine. Because the anesthetic effect of esketamine in human volunteers was found to be more potent than that of arketamine [40, 41], esketamine has been used as an anesthetic in the European Union (EU) and China.

In the research field of mood disorders, (R,S)-ketamine has attracted attention as a rapidly acting antidepressant [36, 42‐46]. In 2000, Berman et al. [47] reported that a single intravenous infusion of (R,S)-ketamine (0.5 mg/kg) produced rapidly acting and sustained antidepressant effects in drug-free patients with MDD. Subsequent studies confirmed robust antidepressant and anti-suicidal effects of (R,S)-ketamine (0.5 mg/kg) in treatment-resistant patients with MDD or BD [48‐52]. (R,S)-ketamine has been widely used as an off-label treatment in the USA and EU, despite the current lack of safety data [53‐55]. In 2019 and 2020, a nasal spray containing esketamine produced by Johnson and Johnson was approved in the USA and EU for treatment-resistant patients with MDD and people at high risk of suicide. However, there are several concerns about the efficacy and approval of esketamine nasal spray [56, 57].

An increasing number of preclinical studies has suggested that arketamine has greater potency and longer lasting antidepressant-like effects than esketamine in rodent models of depression, although the affinity of arketamine at NMDAR is less potent than that of esketamine [58‐66]. Behavioral and biological abnormalities in rodents (i.e., hyperactivity, prepulse inhibition, dopamine release from the synaptic terminal, abuse liability, parvalbumin (PV)-immunoreactivity in the prefrontal cortex (PFC), and heat shock protein HSP-70 expression in the retrosplenial cortex) after injection of arketamine in animals were reduced compared with those after (R,S)-ketamine or esketamine [59, 67‐71].

An open-label pilot study in Brazil reported that a single infusion of arketamine (0.5 mg/kg) caused rapid and sustained antidepressant effects in treatment-resistant patients with MDD [72]. Importantly, side effects (i.e., psychotomimetic and dissociative effects) of arketamine (0.5 mg/kg) in treatment-resistant patients with MDD [72] are substantially less severe than those of esketamine (0.2 and 0.4 mg/kg, i.v.) [73]. Taken together, previous findings suggest that arketamine might provide a novel antidepressant without the side effects of (R,S)-ketamine and esketamine. A phase 2 study of arketamine (or PCN-101) in treatment-resistant patients with MDD is currently being conducted by Perception Neuroscience, Inc. (New York, USA) [39, 46, 74].

It is well known that non-ketamine NMDAR antagonists/modulators do not produce ketamine-like robust antidepressant actions in patients with MDD, suggesting that NMDAR might not play a major role in the antidepressant effects of (R,S)-ketamine in patients with depression [36, 42, 75‐77]. However, the precise molecular and cellular mechanisms underlying the antidepressant effects of arketamine remain elusive [36, 39, 46, 78‐80].

Effects of (R,S)-ketamine and its enantiomers on cognition in healthy subjects

NMDAR antagonists such as PCP and ketamine are known to cause schizophrenia-like symptoms in healthy subjects, including cognitive impairment [12, 13]. In addition to positive and negative symptoms, intravenous administration of (R,S)-ketamine (0.5 mg/kg) produced cognitive impairments in healthy subjects [35]. Furthermore, intravenous administration of esketamine (0.1 mg/kg/min for 5 min and 0.006 mg/kg/min for 60 min) or (R,S)-ketamine (0.2 mg/kg/min for 5 min and 0.012 mg/kg/min for 60 min) to healthy subjects was found to produce significant psychopathological and neurocognitive impairment compared with placebo [81]. Interestingly, esketamine, but not (R,S)-ketamine, significantly increased the auditory alterations subscore of the five-dimensional questionnaire for the assessment of altered states of consciousness, suggesting that arketamine may have a potential protective effect against esketamine-induced psychotomimetic effects [81]. Furthermore, a single intranasal infusion of esketamine (84 mg) in healthy subjects caused a significant cognitive performance impairment at 40 min for all five Cogstate tests, although there were no changes between the esketamine group and the placebo group at 2, 4, or 6 h after infusion [82].

A recent meta-analysis showed acute impairment of cognition in healthy subjects after acute infusion of (R,S)-ketamine or esketamine [83]. Furthermore, verbal learning and memory are the functions most prominently affected in cognitive impairment caused by acute injection of (R,S)-ketamine or esketamine [83]. Thus, it is possible that (R,S)-ketamine and esketamine produce cognitive impairment in healthy subjects.

Effects of (R,S)-ketamine on cognitive impairment in patients with MDD or BD

Clinical studies suggest that (R,S)-ketamine may improve cognitive impairment in patients with mood disorders. Six repeated infusions of (R,S)-ketamine (0.5 mg/kg) were found to ameliorate cognitive impairment (i.e., processing speed) in treatment-resistant patients with MDD or BD [84‐86]. A systematic review revealed that (R,S)-ketamine infusion led to significant improvements in cognitive impairment in treatment-resistant patients with MDD, and (R,S)-ketamine did not worsen cognitive function in depressed patients [87]. Furthermore, the improvement in working memory may be predictive of the anti-suicidal ideation response to (R,S)-ketamine in treatment-resistant patients with MDD [88]. Repeated infusion of (R,S)-ketamine (0.5 mg/kg) caused significant improvement of working memory in MDD patients with PTSD [89]. Interestingly, depression symptom severity and processing speed performance in patients with MDD or BD partially mediated the improvements in suicidal ideation after repeated infusion of (R,S)-ketamine [90]. A recent systematic review indicated potential procognitive effects of subanesthetic doses of (R,S)-ketamine among patients with depression, although there is evidence for immediate altered cognitive dysfunction in healthy subjects [91]. In addition, precognitive effects of (R,S)-ketamine were pronounced in cognitive domains of executive function. A short course of repeated infusion of (R,S)-ketamine (0.5 mg/kg) produced significant improvements in several cognitive domains, including attention, working memory, verbal memory, and visuospatial memory in treatment-resistant patients with MDD [92]. Taken together, these findings suggest that (R,S)-ketamine has beneficial effects on cognitive impairment in depressed patients, although further studies with larger sample sizes are needed.

Patients with MDD or BD typically exhibit a range of negative beliefs, such as worthlessness, hopelessness, and pessimism, and these conditions are considered to be a major public mental health concern [93, 94]. A recent study demonstrated that infusion of (R,S)-ketamine (0.5 mg/kg) improved depressive symptoms in treatment-resistant patients with MDD, and that the improvement was associated with changes in belief-updating processes [95]. These recent data provide new insights into the cognitive mechanisms of action of (R,S)-ketamine in mood disorders.

In contrast, Ochs-Ross et al. [96, 97] reported that intranasal injection of esketamine did not induce any changes in cognitive function of MDD patients from baseline, indicating a lack of beneficial effects of esketamine nasal spray on cognitive impairment.

Effects of ketamine enantiomers on PCP-induced cognitive deficits in rodents

It is well known that NMDAR antagonists such as PCP cause cognitive deficits in rodents. Using the novel object recognition test, we previously reported that repeated administration of PCP (10 mg/kg/day for 10 days) caused cognitive deficits in mice over a long period (more than 6 weeks), and that PCP-induced cognitive deficits could be improved by subsequent sub-chronic administration of clozapine, but not haloperidol [98]. Using the paradigm of PCP-induced cognitive deficits, we reported several candidates for cognitive impairment in psychiatric disorders [99‐103].

We compared the effects of two ketamine enantiomers in a PCP-induced cognitive deficits model. Interestingly, PCP-induced cognitive deficits in mice were ameliorated after subsequent repeated intermittent administration of arketamine (10 mg/kg/day, twice weekly for 2 weeks), but not esketamine (10 mg/kg/day, twice weekly for 2 weeks) [104]. Western blot analysis showed decreased levels of brain-derived neurotrophic factor (BDNF) in the PFC and hippocampus of PCP-treated mice [104]. Furthermore, the beneficial effects of arketamine on cognitive deficits of PCP-treated mice were blocked by pretreatment with TrkB inhibitor ANA-12. These findings suggest that arketamine could ameliorate PCP-induced cognitive deficits via activation of BDNF-TrkB signaling in the brain [104]. Taken together, these findings suggest that arketamine could potentially provide a useful therapeutic drug for cognitive impairment in patients with schizophrenia (Fig. 3).

Cognitive impairment in the prodromal state of psychosis and the potential of arketamine

Cognitive impairment has been shown in the prodromal stage of psychosis [105‐109]. Findings from meta-analyses support neurocognitive dysfunction as a potential detection and prognostic biomarker in individuals at clinical high risk (CHR) for psychosis [106, 107]. Therefore, it is important to treat cognitive impairment in individuals at CHR for psychosis to block the conversion to psychosis.

Epidemiological data suggest that maternal immune activation (MIA), such as maternal infection, might be associated with the risk of neuropsychiatric disorders, such as schizophrenia and ASD in offspring [110, 111]. During the coronavirus disease 2019 (COVID-19) pandemic, an increasing number of pregnant women have become infected with COVID-19 worldwide, and MIA induced by COVID-19 infection has been suggested as a risk factor for schizophrenia and ASD [112‐114]. A cohort study shows that severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exposure in utero may be associated with neurodevelopmental sequelae in some offspring [115].

Toll-like receptor-3 agonist polyriboinosinic–polyribocytidylic acid (poly[I:C]) has been used to establish a rodent model of MIA [116, 117]. Exposure of pregnant mice to poly(I:C) causes cognitive deficits in juvenile offspring [118‐121], and these cognitive deficits in juvenile offspring appear to be similar to the prodromal stage of psychosis.

We investigated whether arketamine could prevent the development of psychosis-like phenotypes in adult offspring after MIA. We examined the effects of arketamine (10 mg/kg/day, twice weekly for 4 weeks) during juvenile and adolescent stages (P28–P56) on the development of cognitive deficits, loss of PV-immunoreactivity in the medial PFC (mPFC), and decreased dendritic spine density in the mPFC and hippocampus from adult offspring after prenatal poly(I:C) exposure [122]. Repeated intermittent administration of arketamine (10 mg/kg/day, twice weekly for 4 weeks) during juvenile and adolescent stages (P28–P56) significantly blocked the development of cognitive deficits, reduced PV-immunoreactivity in the prelimbic (PrL) of mPFC, and decreased dendritic spine density in the PrL of the mPFC, CA3, and dentate gyrus of the hippocampus from adult offspring after MIA. Furthermore, pretreatment with TrkB inhibitor ANA-12 significantly blocked the beneficial effects of arketamine on cognitive deficits of adult offspring after MIA [122]. These data suggest that repeated intermittent administration of arketamine during the juvenile and adolescent stages could prevent the development of psychosis in adult offspring after MIA through activation of BDNF-TrkB signaling. Therefore, it is possible that arketamine represents a useful prophylactic drug to prevent subsequent conversion from UHR to psychosis (Fig. 4).

Dysbiosis of gut microbiota and cognitive impairment of psychiatric disorders

Accumulating evidence suggests the role of dysbiosis of gut microbiota in a variety of psychiatric disorders [123‐126]. A narrative review shows that intervention of gut microbiota can improve cognitive or brain function, suggesting a role of gut microbiota in cognitive performance [127]. A recent population-based study of middle-aged adults demonstrated that microbial community composition on the basis of beta-diversity was associated with all cognitive measures in multivariable-adjusted analysis [128], suggesting a role of gut microbiota in cognitive decline with aging. It has also been suggested that dysbiosis of gut microbiota may play a role in cognitive impairment in patients with psychiatric disorders such as schizophrenia, MDD, and BD [128‐132].

In addition to rapid antidepressant-like effects, arketamine, (R,S)-ketamine, and (S)-norketamine have been suggested to improve abnormal composition of gut microbiota in mice with depression-like behaviors [133‐138]. Furthermore, arketamine could ameliorate abnormal composition of gut microbiota in mouse models of multiple sclerosis [139] and postmenopausal osteoporosis [140]. Considering the beneficial effects of arketamine on dysbiosis of gut microbiota, it is likely that arketamine may improve cognitive impairment in patients of psychiatric disorders through the gut–microbiota–brain axis [36, 42, 44, 125, 126]. Therefore, it is of interest to investigate whether arketamine can improve cognitive impairment and abnormal composition of gut microbiota in patients with psychiatric disorders.

Conclusion and future directions

As stated in the introduction, cognitive impairment is shown in patients with a variety of psychiatric disorders. Neural mechanisms of cognitive impairment between schizophrenia and mood disorders such as MDD and BD may be different. However, a systematic review of MRS studies suggest that abnormal neurotransmission of glutamate and GABA (γ-aminobutyric acid) plays a role in cognitive impairment in patients with schizophrenia and mood disorders such as MDD and BD [141]. Given the role of glutamine–glutamate–GABA cycle in the brain [14, 16, 142], it is possible that abnormalities in the neurotransmission of glutamate and GABA may contribute to cognitive impairment in patients with psychiatric disorders such as schizophrenia and mood disorders. Nonetheless, further study is needed to ascertain the role of glutamate and GABA on cognitive impairment in patients with a variety of psychiatric disorders.

As discussed above, accumulating clinical data suggest that (R,S)-ketamine could improve cognitive impairment in patients with MDD or BD, although it causes cognitive impairment in healthy subjects. Preclinical data suggest that arketamine, but not esketamine, can improve PCP-induced cognitive deficits in rodents [104]. Furthermore, there is evidence that arketamine can ameliorate cognitive deficits in offspring after MIA through activation of BDNF-TrkB signaling [122]. Preclinical findings suggest that BDNF-TrkB signaling could play a role in the beneficial effects of arketamine in several animal models [36, 42‐45, 66, 143‐147]. However, the precise molecular and cellular mechanisms underlying the beneficial effects of arketamine remain elusive [36, 42‐46, 148].

The COVID-19 pandemic began at the end of 2019, and continues to the present. The COVID-19 pandemic causes short-term and long-term mental health problems in survivors after SARS-CoV-2 infection [149‐152]. A recent meta-analysis suggests that half of COVID-19 survivors have a high burden of either physical or mental sequelae (i.e., cognitive impairment) for up to at least 12 months [153]. Additionally, it may be useful to investigate whether arketamine can improve long-term mental sequelae in COVID-19 survivors.

Clinical trials of arketamine in healthy subjects and treatment-resistant patients with MDD are currently being conducted by several pharmaceutical companies, including Perception Neuroscience Inc. (USA), Otsuka Pharmaceutical Co., Ltd. (Japan), Jiangsu HengRui Medicine Co., Ltd. (China), and Jiangsu Enhua Pharmaceutical Co., Ltd. (China) [46]. Given the detrimental effects of cognitive impairment in patients with psychiatric disorders [1], it is of great interest to investigate whether arketamine could improve cognitive impairment in a number of psychiatric disorders, including schizophrenia, MDD, and BD. Finally, future clinical studies are needed to ascertain the efficacy of arketamine on cognitive impairment in patients with psychiatric disorders.

Acknowledgements

The author would like to thank my collaborators who are listed as the co-authors of our papers in the reference list. This study was supported by grants from Japan Society for the Promotion of Science (to K.H., 21H02846, 21H00184, 21H05612). The author thanks Benjamin Knight, MSc., from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Declarations

Conflict of interest

Dr. Hashimoto is the inventor of filed patent applications on “The use of R-ketamine in the treatment of psychiatric diseases”, “(S)-norketamine and salt thereof as pharmaceutical”, “R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “R-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. Dr. Hashimoto has also received speakers’ honoraria, consultant fee, or research support from Abbott, Boehringer Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

Neuer Inhalt

Jetzt informieren

e.Med Neurologie & Psychiatrie

Kombi-Abonnement

Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.

Jetzt testen ²

e.Med Psychiatrie

Kombi-Abonnement

Mit e.Med Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Psychiatrie, den Premium-Inhalten der psychiatrischen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.

Jetzt testen ³

Millan MJ, Agid Y, Brüne M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ, Dubois B, Geyer MA, Goodwin GM, Gorwood P, Jay TM, Joëls M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Spedding M, Sweeney J, Whittington M, Young LJ (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11(2):141–168. https://doi.org/10.1038/nrd3628CrossRefPubMed

Gebreegziabhere Y, Habatmu K, Mihretu A, Cella M, Alem A (2022) Cognitive impairment in people with schizophrenia: an umbrella review. Eur Arch Psychiatry Clin Neurosci 272(7):1139–1155. https://doi.org/10.1007/s00406-022-01416-6CrossRefPubMedPubMedCentral

Kriesche D, Woll CFJ, Tschentscher N, Engel RR, Karch S (2022) Neurocognitive deficits in depression: a systematic review of cognitive impairment in the acute and remitted state. Eur Arch Psychiatry Clin Neurosci. https://doi.org/10.1007/s00406-022-01479-5CrossRefPubMedPubMedCentral

Yoshida T, Suga M, Arima K, Muranaka Y, Tanaka T, Eguchi S, Lin C, Yoshida S, Ishikawa M, Higuchi Y, Seo T, Ueoka Y, Tomotake M, Kaneda Y, Darby D, Maruff P, Iyo M, Kasai K, Higuchi T, Sumiyoshi T, Ohmori T, Takahashi K, Hashimoto K (2011) Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia. PLoS One 6(5):e20469. https://doi.org/10.1371/journal.pone.0020469CrossRefPubMedPubMedCentral

Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M, Hashimoto K (2012) Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7(8):e42676. https://doi.org/10.1371/journal.pone.0042676CrossRefPubMedPubMedCentral

Kitchen H, Rofail D, Herton L, Sacco P (2012) Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv Ther 29(2):148–162. https://doi.org/10.1007/s12325-012-0001-4CrossRefPubMed

Aquila R, Citrome L (2015) Cognitive impairment in schizophrenia: the great unmet need. CNS Spectr 20(Suppl 1):35–39. https://doi.org/10.1017/S109285291500070XCrossRefPubMed

Keefe RS (2016) Treating cognitive impairment in depression: an unmet need. Lancet Psychiatry 3(5):392–393. https://doi.org/10.1016/S2215-0366(16)00095-XCrossRefPubMed

Hashimoto K (2019) Recent advances in the early intervention in schizophrenia: future direction from preclinical findings. Curr Psychiatry Rep 21(8):75. https://doi.org/10.1007/s11920-019-1063-7CrossRefPubMed

10.

Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10):1301–1308. https://doi.org/10.1176/ajp.148.10.1301CrossRefPubMed

11.

Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128(3):419–432. https://doi.org/10.1016/j.pharmthera.2010.07.004CrossRefPubMed

12.

Domino EF, Luby ED (2012) Phencyclidine/schizophrenia: one view toward the past, the other to the future. Schizophr Bull 38(5):914–919. https://doi.org/10.1093/schbul/sbs011CrossRefPubMedPubMedCentral

13.

Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D (2012) Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull 38(5):958–966. https://doi.org/10.1093/schbul/sbs069CrossRefPubMedPubMedCentral

14.

Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263(5):367–377. https://doi.org/10.1007/s00406-013-0399-yCrossRefPubMed

15.

Wiescholleck V, Manahan-Vaughan D (2013) Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis. Neuropharmacology 74:48–58. https://doi.org/10.1016/j.neuropharm.2013.01.001CrossRefPubMed

16.

Hashimoto K (2014) Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets 18(9):1049–1063. https://doi.org/10.1517/14728222.2014.934225CrossRefPubMed

17.

Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC (2018) NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology 142:41–62. https://doi.org/10.1016/j.neuropharm.2017.11.045CrossRefPubMed

18.

Javitt DC (2023) Cognitive impairment associated with schizophrenia: toward novel therapeutics. Annu Rev Pharmacol Toxicol 63:119–141. https://doi.org/10.1146/annurev-pharmtox-051921-093250CrossRefPubMed

19.

Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003) Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60(6):572–576. https://doi.org/10.1001/archpsyc.60.6.572CrossRefPubMed

20.

Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M (2005) Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 29(5):767–769. https://doi.org/10.1016/j.pnpbp.2005.04.023CrossRefPubMed

21.

Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M, Okuno A, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T (2005) Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry 57(12):1493–1503. https://doi.org/10.1016/j.biopsych.2005.03.018CrossRefPubMed

22.

Maekawa M, Ohnishi T, Hashimoto K, Watanabe A, Iwayama Y, Ohba H, Hattori E, Yamada K, Yoshikawa T (2010) Analysis of strain-dependent prepulse inhibition points to a role for Shmt1 (SHMT1) in mice and in schizophrenia. J Neurochem 115(6):1374–1385. https://doi.org/10.1111/j.1471-4159.2010.07039.xCrossRefPubMed

23.

Merritt K, McGuire PK, Egerton A, 1H-MRS in Schizophrenia Investigators, Aleman A, Block W, Bloemen OJN, Borgan F, Bustillo JR, Capizzano AA, Coughlin JM, De la Fuente-Sandoval C, Demjaha A, Dempster K, Do KQ, Du F, Falkai P, Galinska-Skok B, Gallinat J, Gasparovic C, Ginestet CE, Goto N, Graff-Guerrero A, Ho BC, Howes OD, Jauhar S, Jeon P, Kato T, Kaufmann CA, Kegeles LS, Keshavan M, Kim SY, Kunugi H, Lauriello J, Liemburg EJ, Mcilwain ME, Modinos G, Mouchlianitis ED, Nakamura J, Nenadic I, Öngür D, Ota M, Palaniyappan L, Pantelis C, Plitman E, Posporelis S, Purdon SE, Reichenbach JR, Renshaw PF, Russell BR, Sawa A, Schaefer M, Shungu DC, Smesny S, Stanley JA, Stone JM, Szulc A, Taylor R, Thakkar K, Théberge J, Tibbo PG, van Amelsvoort T, Walecki J, Williamson PC, Wood SJ, Xin L, Yamasue H (2021) Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: a mega-analysis of individual participant-level data. JAMA Psychiat 78(6):667–681. https://doi.org/10.1001/jamapsychiatry.2021.0380CrossRef

24.

Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62(11):1310–1316. https://doi.org/10.1016/j.biopsych.2007.03.017CrossRefPubMed

25.

Hashimoto K (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61(2):105–123. https://doi.org/10.1016/j.brainresrev.2009.05.005CrossRefPubMed

26.

Tokita K, Yamaji T, Hashimoto K (2012) Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav 100(4):688–704. https://doi.org/10.1016/j.pbb.2011.04.016CrossRefPubMed

27.

Ohgi Y, Futamura T, Hashimoto K (2015) Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med 15(3):206–221. https://doi.org/10.2174/1566524015666150330143008CrossRefPubMed

28.

Hashimoto K, Yoshida T, Ishikawa M, Fujita Y, Niitsu T, Nakazato M, Watanabe H, Sasaki T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M (2016) Increased serum levels of serine enantiomers in patients with depression. Acta Neuropsychiatr 28(3):173–178. https://doi.org/10.1017/neu.2015.59CrossRefPubMed

29.

Hashimoto K, Bruno D, Nierenberg J, Marmar CR, Zetterberg H, Blennow K, Pomara N (2016) Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. Transl Psychiatry 6(3):e744. https://doi.org/10.1038/tp.2016.8CrossRefPubMedPubMedCentral

30.

Moriguchi S, Takamiya A, Noda Y, Horita N, Wada M, Tsugawa S, Plitman E, Sano Y, Tarumi R, ElSalhy M, Katayama N, Ogyu K, Miyazaki T, Kishimoto T, Graff-Guerrero A, Meyer JH, Blumberger DM, Daskalakis ZJ, Mimura M, Nakajima S (2019) Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Mol Psychiatry 24(7):952–964. https://doi.org/10.1038/s41380-018-0252-9CrossRefPubMed

31.

Chabert J, Allauze E, Pereira B, Chassain C, De Chazeron I, Rotgé JY, Fossati P, Llorca PM, Samalin L (2022) Glutamatergic and N-acetylaspartate metabolites in bipolar disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Int J Mol Sci 23(16):8974. https://doi.org/10.3390/ijms23168974CrossRefPubMedPubMedCentral

32.

Shirayama Y, Takahashi M, Osone F, Hara A, Okubo T (2017) Myo-inositol, glutamate, and glutamine in the prefrontal cortex, hippocampus, and amygdala in major depression. Biol Psychiatry Cogn Neurosci Neuroimaging 2(2):196–204. https://doi.org/10.1016/j.bpsc.2016.11.006CrossRefPubMed

33.

Chang CH, Lane HY, Tseng PT, Chen SJ, Liu CY, Lin CH (2019) Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials. J Psychopharmacol 33(4):436–448. https://doi.org/10.1177/0269881118822157CrossRefPubMed

34.

Kuo CY, Lin CH, Lane HY (2021) Molecular basis of late-life depression. Int J Mol Sci 22(14):7421. https://doi.org/10.3390/ijms22147421CrossRefPubMedPubMedCentral

35.

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199–214. https://doi.org/10.1001/archpsyc.1994.03950030035004CrossRefPubMed

36.

Wei Y, Chang L, Hashimoto K (2022) Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry 27(1):559–573. https://doi.org/10.1038/s41380-021-01121-1CrossRefPubMed

37.

Tan Y, Hashimoto K (2021) Predictable biomarkers for rapid-acting antidepressant response to ketamine. In: Hashimoto K, Manto M (eds) New Rapid-acting Antidepressants. Springer Nature, Switzerland, pp 31–48CrossRef

38.

Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113(3):678–684. https://doi.org/10.1097/ALN.0b013e3181ed09a2CrossRefPubMed

39.

Hashimoto K (2022) Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic? Mol Psychiatry 27(8):3116–3118. https://doi.org/10.1038/s41380-022-01587-7CrossRefPubMed

40.

White PF, Schüttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ (1985) Comparative pharmacology of the ketamine isomers. Studies in voluntters. Br J Anaesth 57(2):197–203. https://doi.org/10.1093/bja/57.2.197CrossRefPubMed

41.

Hirota K, Lamber DG (2022) Ketamine; history and role in anesthetic pharmacology. Neuropharmacology 216:109171. https://doi.org/10.1016/j.neuropharm.2022.109171CrossRefPubMed

42.

Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci 73(10):613–627. https://doi.org/10.1111/pcn.12902. (Epub 2019 Jul 11)CrossRefPubMedPubMedCentral

43.

Yang C, Yang J, Luo A, Hashimoto K (2019) Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry 9(1):280. https://doi.org/10.1038/s41398-019-0624-1CrossRefPubMedPubMedCentral

44.

Hashimoto K (2020) Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol 177:113935. https://doi.org/10.1016/j.bcp.2020.113935CrossRefPubMed

45.

Wei Y, Chang L, Hashimoto K (2020) A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol Biochem Behav 190:172870. https://doi.org/10.1016/j.pbb.2020.172870CrossRefPubMed

46.

Zhang J, Yao W, Hashimoto K (2022) Arketamine, a new rapid-acting antidepressant: a historical review and future directions. Neuropharmacology 21:109219. https://doi.org/10.1016/j.neuropharm.2022.109219CrossRef

47.

Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351–354. https://doi.org/10.1016/s0006-3223(99)00230-9CrossRefPubMed

48.

Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856–864. https://doi.org/10.1001/archpsyc.63.8.856CrossRefPubMed

49.

Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67(8):793–802. https://doi.org/10.1001/archgenpsychiatry.2010.90CrossRefPubMedPubMedCentral

50.

Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, Tu PC, Bai YM, Cheng CM, Krystal JH (2017) Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology 42(13):2482–2492. https://doi.org/10.1038/npp.2017.94CrossRefPubMedPubMedCentral

51.

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI (2020) Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 25(7):1592–1603. https://doi.org/10.1038/s41380-018-0256-5CrossRefPubMed

52.

Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA Jr, Sanacora G (2018) The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry 175(2):150–158. https://doi.org/10.1176/appi.ajp.2017.17040472CrossRefPubMed

53.

López-Díaz Á, Murillo-Izquierdo M, Moreno-Mellado E (2019) Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective. Br J Psychiatry 215(2):447–448. https://doi.org/10.1192/bjp.2019.102CrossRefPubMed

54.

Lengvenyte A, Strumila R, Olié E, Courtet P (2022) Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how? Eur Neuropsychopharmacol 57:88–104. https://doi.org/10.1016/j.euroneuro.2022.02.004CrossRefPubMed

55.

O’Brien B, Wilkinson ST, Mathew SJ (2022) An update on community ketamine practices. Am J Psychiatry 179(5):393–394. https://doi.org/10.1176/appi.ajp.21111086CrossRefPubMed

56.

Turner E (2019) Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry 6(12):977–979. https://doi.org/10.1016/S2215-0366(19)30394-3CrossRefPubMed

57.

Horowitz MA, Moncrieff J (2021) Are we repeating mistakes of the past? A review of the evidence for esketamine. Br J Psychiatry 219(5):618. https://doi.org/10.1192/bjp.2020.89CrossRefPubMed

58.

Zhang JC, Li SX, Hashimoto K (2014) R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137–141. https://doi.org/10.1016/j.pbb.2013.11.033CrossRefPubMed

59.

Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5(9):e632. https://doi.org/10.1038/tp.2015.136CrossRefPubMedPubMedCentral

60.

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533(7604):481–486. https://doi.org/10.1038/nature17998CrossRefPubMedPubMedCentral

61.

Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K, Chaki S (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361(1):9–16. https://doi.org/10.1124/jpet.116.239228CrossRefPubMed

62.

Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K (2017) (R)-ketamine shows greater potency and longer lasting abtidepressant effects than its metabolites (2R,6R)-hydroxynorketamine. Biol Psychiatry 82(5):e43–e44. https://doi.org/10.1016/j.biopsych.2016.12.020CrossRefPubMed

63.

Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, Hashimoto K (2018) Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry 83(1):18–28. https://doi.org/10.1016/j.biopsych.2017.05.016CrossRefPubMed

64.

Chang L, Zhang K, Pu Y, Qu Y, Wang SM, Xiong Z, Ren Q, Dong C, Fujita Y, Hashimoto K (2019) Comparison of antidepressant and side effects in mice after intranasal administration of (R, S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav 181:53–59. https://doi.org/10.1016/j.pbb.2019.04.008CrossRefPubMed

65.

Zhu J, Hawkins E, Phillips K, Deshpande LS (2020) Assessment of ketamine and its enantiomers in an organophosphate-based rat model for features of Gulf War illness. Int J Environ Res Public Health 17(13):4710. https://doi.org/10.3390/ijerph17134710CrossRefPubMedPubMedCentral

66.

Yao W, Cao Q, Luo S, He L, Yang C, Chen J, Qi Q, Hashimoto K, Zhang JC (2022) Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Mol Psychiatry 27(3):1618–1629. https://doi.org/10.1038/s41380-021-01377-7CrossRefPubMed

67.

Yang C, Han M, Zhang JC, Ren Q, Hashimoto K (2016) Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 239:281–283. https://doi.org/10.1016/j.psychres.2016.03.034CrossRefPubMed

68.

Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H (2017) Reduction of dopamine D_2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 267(2):173–176. https://doi.org/10.1007/s00406-016-0692-7CrossRefPubMed

69.

Tian Z, Dong C, Fujita A, Fujita Y, Hashimoto K (2018) Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R, S)-ketamine and (S)-ketamine, but not (R)-ketamine. Pharmacol Biochem Behav 172:17–21. https://doi.org/10.1016/j.pbb.2018.07.003CrossRefPubMed

70.

Tan Y, Hashimoto K (2020) Risk of psychosis after repeated intermittent administration of (S)-ketamine, but not (R)-ketamine, in mice. J Affect Disord 269:198–200. https://doi.org/10.1016/j.jad.2020.03.040CrossRefPubMed

71.

Bonaventura J, Lam S, Carlton M, Boehm MA, Gomez JL, Solís O, Sánchez-Soto M, Morris PJ, Fredriksson I, Thomas CJ, Sibley DR, Shaham Y, Zarate CA Jr, Michaelides M (2021) Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry 26(11):6704–6722. https://doi.org/10.1038/s41380-021-01093-2CrossRefPubMedPubMedCentral

72.

Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda ALT, Quarantini LC (2021) Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci 271(3):577–582. https://doi.org/10.1007/s00406-020-01110-5CrossRefPubMed

73.

Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, Van Nueten L (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80(6):424–431. https://doi.org/10.1016/j.biopsych.2015.10.018CrossRefPubMed

74.

Chang L, Hashimoto K (2022) Comments to behavioral tests for antidepressant-like actions of (2R,6R)-hydroxynorketamine by Bonaventura et al. Mol Psychiatry. https://doi.org/10.1038/s41380-022-01766-6CrossRefPubMedPubMedCentral

75.

Hashimoto K (2016) Ketamine’s antidepressant action: beyond NMDA receptor inhibition. Expert Opin Ther Targets 20(11):1389–1392. https://doi.org/10.1080/14728222.2016.1238899CrossRefPubMed

76.

Hashimoto K (2020) Are NMDA and opioid receptors involved in the antidepressant actions of ketamine? Proc Natl Acad Sci USA 117(21):11200–11201. https://doi.org/10.1073/pnas.2001264117CrossRefPubMedPubMedCentral

77.

Ma L, Hashimoto K (2022) The role of hippocampal KCNQ2 channel in antidepressant actions of ketamine. Neuron 110(14):2201–2203. https://doi.org/10.1016/j.neuron.2022.05.027CrossRefPubMed

78.

Jelen LA, Young AH, Stone JM (2021) Ketamine: a tale of two enantiomers. J Psychopharmacol 35(2):109–123. https://doi.org/10.1177/0269881120959644CrossRefPubMed

79.

Scotton E, Antqueviezc B, Vasconcelos MF, Dalpiaz G, Paul Géa L, Ferraz Goularte J, Colombo R, Ribeiro Rosa A (2022) Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers. Biochem Pharmacol 198:114963. https://doi.org/10.1016/j.bcp.2022.114963CrossRefPubMed

80.

Wang X, Yang J, Hashimoto K (2022) (R)-ketamine as prophylactic and therapeutic drug for neurological disorders: beyond depression. Neurosci Biobehav Rev 139:104762. https://doi.org/10.1016/j.neubiorev.2022.104762CrossRefPubMed

81.

Passie T, Adams HA, Logemann F, Brandt SD, Wiese B, Karst M (2021) Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers. Eur Neuropsychopharmacol 44:92–104. https://doi.org/10.1016/j.euroneuro.2021.01.005CrossRefPubMed

82.

Morrison RL, Fedgchin M, Singh J, Van Gerven J, Zuiker R, Lim KS, van der Ark P, Wajs E, Xi L, Zannikos P, Drevets WC (2018) Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology 235(4):1107–1119. https://doi.org/10.1007/s00213-018-4828-5CrossRefPubMedPubMedCentral

83.

Zhornitsky S, Tourjman V, Pelletier J, Assaf R, Li CR, Potvin S (2022) Acute effects of ketamine and esketamine on cognition in healthy subjects: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 118:110575. https://doi.org/10.1016/j.pnpbp.2022.110575CrossRefPubMed

84.

Zhou Y, Zheng W, Liu W, Wang C, Zhan Y, Li H, Chen L, Li M, Ning Y (2018) Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. Brain Behav Immun 74:205–212. https://doi.org/10.1016/j.bbi.2018.09.007CrossRefPubMed

85.

Zhou Y, Zheng W, Liu W, Wang C, Zhan Y, Li H, Chen L, Li M, Ning Y (2018) Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. J Psychopharmacol 32(10):1118–1126. https://doi.org/10.1177/0269881118798614CrossRefPubMed

86.

Shiroma PR, Thuras P, Wels J, Albott CS, Erbes C, Tye S, Kim KO (2020) Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 277:470–477. https://doi.org/10.1016/j.jad.2020.08.058CrossRefPubMed

87.

Gill H, Gill B, Rodrigues NB, Lipsitz O, Rosenblat JD, El-Halabi S, Nasri F, Mansur RB, Lee Y, McIntyre RS (2021) The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research. Neurosci Biobehav Rev 120:78–85. https://doi.org/10.1016/j.neubiorev.2020.11.020CrossRefPubMed

88.

Chen X, Wang M, Hu Y, Zhan Y, Zhou Y, Zheng W, Liu W, Wang C, Zhong X, Li H, Lan X, Ning Y, Zhang B (2021) Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients. Eur Arch Psychiatry Clin Neurosci 271(3):431–438. https://doi.org/10.1007/s00406-020-01221-zCrossRefPubMed

89.

Albott CS, Lim KO, Erbes C, Thuras P, Wels J, Tye SJ, Shiroma PR (2022) Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder. J Affect Disord 308:289–297. https://doi.org/10.1016/j.jad.2022.04.066CrossRefPubMed

90.

Zhou Y, Wang C, Lan X, Li W, Chao Z, Wu K, McIntyre RS, Ning Y (2022) Cognitive function mediates the anti-suicide effect of repeated intravenous ketamine in adult patients with suicidal ideation. Front Psychiatry 13:779326. https://doi.org/10.3389/fpsyt.2022.779326CrossRefPubMedPubMedCentral

91.

Shiroma PR, Velit-Salazar MR, Vorobyov Y (2022) A systematic review of neurocognitive effects of subanesthetic doses of intravenous ketamine in major depressive disorder, post-traumatic stress disorder, and healthy population. Clin Drug Investig 42(7):549–566. https://doi.org/10.1007/s40261-022-01169-zCrossRefPubMed

92.

Phillips JL, Van Geel A, Burhunduli P, Vasudev D, Batten LA, Norris S, Talbot J, Ortiz A, Owoeye O, Blier P (2022) Assessment of objective and subjective cognitive function in patients with treatment-resistant depression undergoing repeated ketamine infusions. Int J Neuropsychopharmacol 25(12):992–1002. https://doi.org/10.1093/ijnp/pyac045CrossRefPubMedPubMedCentral

93.

Beck AT (2008) The evolution of the cognitive model of depression and its neurobiological correlates. Am J Psychiatry 165(8):969–977. https://doi.org/10.1176/appi.ajp.2008.08050721CrossRefPubMed

94.

Favaretto E, Bedani F, Offredi A, Schroffenegger M, Sassaroli S, Ruggiero G, Fagiolini A, Caselli G (2020) Metacognitions and repetitive negative thinking in bipolar disorder and healthy controls: a comparative study. J Affect Disord 276:152–158. https://doi.org/10.1016/j.jad.2020.07.013CrossRefPubMed

95.

Bottemanne H, Morlaas O, Claret A, Sharot T, Fossati P, Schmidt L (2022) Evaluation of early ketamine effects on belief-updating biases in patients with treatment-resistant depression. JAMA Psychiat 79(11):1124–1132. https://doi.org/10.1001/jamapsychiatry.2022.2996CrossRef

96.

Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, Steffens DC, Adler C, McShane R, Gaillard R, Wilkinson ST, Singh JB (2020) Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry 228(2):121–141. https://doi.org/10.1016/j.jagp.2019.10.008CrossRef

97.

Ochs-Ross R, Wajs E, Daly EJ, Zhang Y, Lane R, Lim P, Drevets WC, Steffens DC, Sanacora G, Jamieson C, Hough D, Manji H, Singh JB (2022) Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: post-hoc analysis of SUSTAIN-2, a long-term open-label phase 3 safety and efficacy study. Am J Geriatr Psychiatry 30(5):541–556. https://doi.org/10.1016/j.jagp.2021.09.014CrossRefPubMed

98.

Hashimoto K, Fujita Y, Iyo M (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol 519(1–2):114–117. https://doi.org/10.1016/j.ejphar.2005.07.002CrossRefPubMed

99.

Hashimoto K, Fujita Y, Ishima T, Hagiwara H, Iyo M (2006) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of alpha-7 nicotinic receptors. Eur J Pharmacol 553(1–3):191–195. https://doi.org/10.1016/j.ejphar.2006.09.055CrossRefPubMed

100.

Hashimoto K, Fujita Y, Iyo M (2007) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 32(3):514–521. https://doi.org/10.1038/sj.npp.1301047CrossRefPubMed

101.

Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, Tsukada H, Iyo M (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry 63(1):92–97. https://doi.org/10.1016/j.biopsych.2007.04.034CrossRefPubMed

102.

Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol 18(6):414–421. https://doi.org/10.1016/j.euroneuro.2007.07.009CrossRefPubMed

103.

Yoshimi N, Fujita Y, Ohgi Y, Futamura T, Kikuchi T, Hashimoto K (2014) Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT_1A receptors. Pharmacol Biochem Behav 124:245–249. https://doi.org/10.1016/j.pbb.2014.06.008CrossRefPubMed

104.

Tan Y, Fujita Y, Qu Y, Chang L, Pu Y, Wang S, Wang X, Hashimoto K (2020) Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: role of BDNF-TrkB signaling. Pharmacol Biochem Behav 188:172839. https://doi.org/10.1016/j.pbb.2019.172839CrossRefPubMed

105.

Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, Stieglitz RD, Vita A, McGuire P, Borgwardt S (2012) Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 69(6):562–571. https://doi.org/10.1001/archgenpsychiatry.2011.1592CrossRefPubMed

106.

Catalan A, Salazar de Pablo G, Aymerich C, Damiani S, Sordi V, Radua J, Oliver D, McGuire P, Giuliano AJ, Stone WS, Fusar-Poli P (2021) Neurocognitive functioning in individuals at clinical high risk for psychosis: a systematic review and meta-analysis. JAMA Psychiat 78(8):859–867. https://doi.org/10.1001/jamapsychiatry.2021.1290CrossRef

107.

Catalan A, Radua J, McCutcheon R, Aymerich C, Pedruzo B, González-Torres MÁ, Baldwin H, Stone WS, Giuliano AJ, McGuire P, Fusar-Poli P (2022) Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis. Transl Psychiatry 12(1):198. https://doi.org/10.1038/s41398-022-01961-7CrossRefPubMedPubMedCentral

108.

Haining K, Gajwani R, Gross J, Gumley AI, Ince RAA, Lawrie SM, Schultze-Lutter F, Schwannauer M, Uhlhaas PJ (2022) Characterising cognitive heterogeneity in individuals at clinical high-risk for psychosis: a cluster analysis with clinical and functional outcome prediction. Eur Arch Psychiatry Clin Neurosci 272(3):437–448. https://doi.org/10.1007/s00406-021-01315-2CrossRefPubMed

109.

Millman ZB, Roemer C, Vargas T, Schiffman J, Mittal VA, Gold JM (2022) Neuropsychological performance among individuals at clinical high-risk for psychosis vs putatively low-risk peers with other psychopathology: a systematic review and meta-analysis. Schizophr Bull 48(5):999–1010. https://doi.org/10.1093/schbul/sbac031CrossRefPubMedPubMedCentral

110.

Brown AS, Meyer U (2018) Maternal immune activation and neuropsychiatric illness: a translational research perspective. Am J Psychiatry 175(11):1073–1083. https://doi.org/10.1176/appi.ajp.2018.17121311CrossRefPubMedPubMedCentral

111.

Guma E, Plitman E, Chakravarty MM (2019) The role of maternal immune activation in altering the neurodevelopmental trajectories of offspring: a translational review of neuroimaging studies with implications for autism spectrum disorder and schizophrenia. Neurosci Biobehav Rev 104:141–157. https://doi.org/10.1016/j.neubiorev.2019.06.020CrossRefPubMed

112.

Hashimoto K (2021) Risk of neuropsychiatric disorders in offspring of COVID-19-infected pregnant women and nutritional intervention. Eur Arch Psychiatry Clin Neurosci 271(2):387–389. https://doi.org/10.1007/s00406-020-01148-5CrossRefPubMed

113.

Hashimoto Y, Suzuki T, Hashimoto K (2022) Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry 27(4):1898–1907. https://doi.org/10.1038/s41380-021-01432-3CrossRefPubMedPubMedCentral

114.

Wang R, Wu Z, Huang C, Hashimoto K, Yang L, Yang C (2022) Deleterious effects of nervous system in the offspring following maternal SARS-CoV-2 infection during the COVID-19 pandemic. Transl Psychiatry 12(1):232. https://doi.org/10.1038/s41398-022-01985-zCrossRefPubMedPubMedCentral

115.

Edlow AG, Castro VM, Shook LL, Kaimal AJ, Perlis RH (2022) Neurodevelopmental outcomes at 1 year in infants of mothers who tested positive for SARS-CoV-2 during pregnancy. JAMA Netw Open 5(6):e2215787. https://doi.org/10.1001/jamanetworkopen.2022.15787CrossRefPubMedPubMedCentral

116.

Haddad FL, Patel SV, Schmid S (2020) Maternal immune activation by poly I: C as a preclinical model for neurodevelopmental disorders: a focus on autism and schizophrenia. Neurosci Biobehav Rev 113:546–567. https://doi.org/10.1016/j.neubiorev.2020.04.012CrossRefPubMed

117.

Woods RM, Lorusso JM, Potter HG, Neill JC, Glazier JD, Hager R (2021) Maternal immune activation in rodent models: a systematic review of neurodevelopmental changes in gene expression and epigenetic modulation in the offspring brain. Neurosci Biobehav Rev 129:389–421. https://doi.org/10.1016/j.neubiorev.2021.07.015CrossRefPubMed

118.

Han M, Zhang JC, Yao W, Yang C, Ishima T, Ren Q, Ma M, Dong C, Huang XF, Hashimoto K (2016) Intake of 7,8-dihydroxyflavone during juvenile and adolescent stages prevents onset of psychosis in adult offspring after maternal immune activation. Sci Rep 6:36087. https://doi.org/10.1038/srep36087CrossRefPubMedPubMedCentral

119.

Fujita Y, Ishima T, Hashimoto K (2016) Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation. Sci Rep 6:37261. https://doi.org/10.1038/srep37261CrossRefPubMedPubMedCentral

120.

Matsuura A, Ishima T, Fujita Y, Iwayama Y, Hasegawa S, Kawahara-Miki R, Maekawa M, Toyoshima M, Ushida Y, Suganuma H, Kida S, Yoshikawa T, Iyo M, Hashimoto K (2018) Dietary glucoraphanin prevents the onset of psychosis in the adult offspring after maternal immune activation. Sci Rep 8(1):2158. https://doi.org/10.1038/s41598-018-20538-3CrossRefPubMedPubMedCentral

121.

Ma M, Ren Q, Yang J, Zhang K, Xiong Z, Ishima T, Pu Y, Hwang SH, Toyoshima M, Iwayama Y, Hisano Y, Yoshikawa T, Hammock BD, Hashimoto K (2019) Key role of soluble epoxide hydrolase in the neurodevelopmental disorders of offspring after maternal immune activation. Proc Natl Acad Sci USA 116(14):7083–7088. https://doi.org/10.1073/pnas.1819234116CrossRefPubMedPubMedCentral

122.

Tan Y, Fujita Y, Pu Y, Chang L, Qu Y, Wang X, Hashimoto K (2022) Repeated intermittent administration of (R)-ketamine during juvenile and adolescent stages prevents schizophrenia-relevant phenotypes in adult offspring after maternal immune activation: a role of TrkB signaling. Eur Arch Psychiatry Clin Neurosci 272(4):693–701. https://doi.org/10.1007/s00406-021-01365-6CrossRefPubMedPubMedCentral

123.

McGuinness AJ, Davis JA, Dawson SL, Loughman A, Collier F, O’Hely M, Simpson CA, Green J, Marx W, Hair C, Guest G, Mohebbi M, Berk M, Stupart D, Watters D, Jacka FN (2022) A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol Psychiatry 27(4):1920–1935. https://doi.org/10.1038/s41380-022-01456-3CrossRefPubMedPubMedCentral

124.

Shoubridge AP, Choo JM, Martin AM, Keating DJ, Wong ML, Licinio J, Rogers GB (2022) The gut microbiome and mental health: advances in research and emerging priorities. Mol Psychiatry 27(4):1908–1919. https://doi.org/10.1038/s41380-022-01479-wCrossRefPubMed

125.

Chang L, Wei Y, Hashimoto K (2022) Brain-gut-microbiota axis in depression: a historical overview and future directions. Brain Res Bull 182:44–56. https://doi.org/10.1016/j.brainresbull.2022.02.004CrossRefPubMed

126.

Wei Y, Wang T, Liao L, Fan X, Chang L, Hashimoto K (2022) Brain-spleen axis in health and diseases: a review and future perspective. Brain Res Bull 182:130–140. https://doi.org/10.1016/j.brainresbull.2022.02.008CrossRefPubMed

127.

Tooley KL (2020) Effects of the human gut microbiota on cognitive performance, brain structure and function: a narrative review. Nutrients 12(10):3009. https://doi.org/10.3390/nu12103009CrossRefPubMedPubMedCentral

128.

Meyer K, Lulla A, Debroy K, Shikany JM, Yaffe K, Meirelles O, Launer LJ (2022) Association of the gut microbiota with cognitive function in midlife. JAMA Netw Open 5(2):e2143941. https://doi.org/10.1001/jamanetworkopen.2021.43941CrossRefPubMedPubMedCentral

129.

Zeng C, Yang P, Cao T, Gu Y, Li N, Zhang B, Xu P, Liu Y, Luo Z, Cai H (2021) Gut microbiota: an intermediary between metabolic syndrome and cognitive deficits in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 106:110097. https://doi.org/10.1016/j.pnpbp.2020.110097CrossRefPubMed

130.

Bioque M, González-Rodríguez A, Garcia-Rizo C, Cobo J, Monreal JA, Usall J, Soria V, PNECAT Group, Labad J (2021) Targeting the microbiome-gut-brain axis for improving cognition in schizophrenia and major mood disorders: a narrative review. Prog Neuropsychopharmacol Biol Psychiatry 105:110130. https://doi.org/10.1016/j.pnpbp.2020.110130CrossRefPubMed

131.

Dai W, Liu J, Qiu Y, Teng Z, Li S, Yuan H, Huang J, Xiang H, Tang H, Wang B, Chen J, Wu H (2022) Gut microbial dysbiosis and cognitive impairment in bipolar disorder: current evidence. Front Pharmacol 13:893567. https://doi.org/10.3389/fphar.2022.893567CrossRefPubMedPubMedCentral

132.

Dobielska M, Bartosik NK, Zyzik KA, Kowalczyk E, Karbownik MS (2022) Mechanisms of cognitive impairment in depression. May probiotics help? Front Psychiatry 13:904426. https://doi.org/10.3389/fpsyt.2022.904426CrossRefPubMedPubMedCentral

133.

Qu Y, Yang C, Ren Q, Ma M, Dong C, Hashimoto K (2017) Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model. Sci Rep 7(1):15725. https://doi.org/10.1038/s41598-017-16060-7CrossRefPubMedPubMedCentral

134.

Yang C, Qu Y, Fujita Y, Ren Q, Ma M, Dong C, Hashimoto K (2017) Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model. Transl Psychiatry 7(12):1294. https://doi.org/10.1038/s41398-017-0031-4CrossRefPubMedPubMedCentral

135.

Ma L, Wang L, Chang L, Shan J, Qu Y, Wang X, Fujita Y, Hashimoto K (2022) A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model. Neuropharmacology 219:109250. https://doi.org/10.1016/j.neuropharm.2022.109250CrossRefPubMed

136.

Huang N, Hua D, Zhan G, Li S, Zhu B, Jiang R, Yang L, Bi J, Xu H, Hashimoto K, Luo A, Yang C (2019) Role of Actinobacteria and Coriobacteriia in the antidepressant effects of ketamine in an inflammation model of depression. Pharmacol Biochem Behav 176:93–100. https://doi.org/10.1016/j.pbb.2018.12.001CrossRefPubMed

137.

Wang Y, Jiang R, Wu Z, Zhou L, Xu J, Huang C, Yang L, Zhu B, Yan E, Liu C, Yang C (2021) Gut microbiota is involved in the antidepressant-like effect of (S)-norketamine in an inflammation model of depression. Pharmacol Biochem Behav 207:173226. https://doi.org/10.1016/j.pbb.2021.173226CrossRefPubMed

138.

Hua H, Huang C, Liu H, Xu X, Xu X, Wu Z, Liu C, Wang Y, Yang C (2022) Depression and antidepressant effects of ketamine and its metabolites: The pivotal role of gut microbiota. Neuropharmacology 220:109272. https://doi.org/10.1016/j.neuropharm.2022.109272CrossRefPubMed

139.

Wang X, Chang L, Wan X, Tan Y, Qu Y, Shan J, Yang Y, Ma L, Hashimoto K (2022) (R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: a role of gut-microbiota-brain axis. Neurobiol Dis 165:105635. https://doi.org/10.1016/j.nbd.2022.105635CrossRefPubMed

140.

Wan X, Eguchi A, Fujita Y, Ma L, Wang X, Yang Y, Qu Y, Chang L, Zhang J, Mori C, Hashimoto K (2022) Effects of (R)-ketamine on reduced bone mineral density in ovariectomized mice: a role of gut microbiota. Neuropharmacology 213:109139. https://doi.org/10.1016/j.neuropharm.2022.109139CrossRefPubMed

141.

Reddy-Thootkur M, Kraguljac NV, Lahti AC (2022) The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - a systematic review of magnetic resonance spectroscopy studies. Schizophr Res 249:74–84. https://doi.org/10.1016/j.schres.2020.02.001CrossRefPubMed

142.

Hashimoto K (2014) Abnormalities of the glutamine-glutamate-GABA cycle in the schizophrenia brain. Schizophr Res 156(2–3):281–282. https://doi.org/10.1016/j.schres.2014.04.008CrossRefPubMed

143.

Fujita A, Fujita Y, Pu Y, Chang L, Hashimoto K (2020) MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling. Psychopharmacology 2237(1):83–92. https://doi.org/10.1007/s00213-019-05346-5CrossRef

144.

Fujita Y, Hashimoto Y, Hashimoto H, Chang L, Hashimoto K (2021) Dextran sulfate sodium-induced inflammation and colitis in mice are ameliorated by (R)-ketamine, but not (S)-ketamine: a role of TrkB signaling. Eur J Pharmacol 897:173954. https://doi.org/10.1016/j.ejphar.2021.173954CrossRefPubMed

145.

Qu Y, Shan J, Wang S, Chang L, Pu Y, Wang X, Tan Y, Yamamoto M, Hashimoto K (2021) Rapid-acting and long-lasting antidepressant-like action of (R)-ketamine in Nrf2 knock-out mice: a role of TrkB signaling. Eur Arch Psychiatry Clin Neurosci 271(3):439–446. https://doi.org/10.1007/s00406-020-01208-wCrossRefPubMed

146.

He T, Wu Z, Zhang X, Liu H, Wang Y, Jiang R, Liu C, Hashimoto K, Yang C (2022) A bibliometric analysis of research on the role of BDNF in depression and treatment. Biomolecules 12(10):1464. https://doi.org/10.3390/biom12101464CrossRefPubMedPubMedCentral

147.

He T, Wang D, Wu Z, Huang C, Xu X, Xu X, Liu C, Hashimoto K, Yang C (2022) A bibliometric analysis of research on (R)-ketamine from 2002 to 2021. Neuropharmacology 218:109207. https://doi.org/10.1016/j.neuropharm.2022.109207CrossRefPubMed

148.

Zhang K, Yao Y, Hashimoto K (2023) Ketamine and its metabolites: potential as novel treatments for depression. Neuropharmacology 222:109305. https://doi.org/10.1016/j.neuropharm.2022.109305CrossRefPubMed

149.

Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, Lekoubou A, Oh JS, Ericson JE, Ssentongo P, Chinchilli VM (2021) Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 4:e2128568. https://doi.org/10.1001/jamanetworkopen.2021.28568CrossRefPubMedPubMedCentral

150.

Damiano RF, Guedes BF, de Rocca CC, de Pádua SA, Castro LHM, Munhoz CD, Nitrini R, Filho GB, Miguel EC, Lucchetti G, Forlenza O (2022) Cognitive decline following acute viral infections: literature review and projections for post-COVID-19. Eur Arch Psychiatry Clin Neurosci 272(1):139–154. https://doi.org/10.1007/s00406-021-01286-4CrossRefPubMed

151.

Hashimoto K (2022) Mental health during the COVID-19 pandemic, impact of childhood trauma in psychiatric disorders, and predictable biomarkers for bipolar disorder. Eur Arch Psychiatry Clin Neurosci 272(5):753–755. https://doi.org/10.1007/s00406-022-01445-1CrossRefPubMedPubMedCentral

152.

Hashimoto Y, Suzuki T, Hashimoto K (2022) Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki. Mol Psychiatry 27(9):3563–3564. https://doi.org/10.1038/s41380-022-01546-2CrossRefPubMedPubMedCentral

153.

Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, Ni SY, Mei H, Yuan K, Shi L, Li P, Fan TT, Yuan JL, Vitiello MV, Kosten T, Kondratiuk AL, Sun HQ, Tang XD, Liu MY, Lalvani A, Shi J, Bao YP, Lu L (2023) A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry 28(1):423–433. https://doi.org/10.1038/s41380-022-01614-7CrossRefPubMed

Titel: Arketamine for cognitive impairment in psychiatric disorders
verfasst von: Kenji Hashimoto
Publikationsdatum: 14.02.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 7/2023
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-023-01570-5

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Brief history of (R,S)-ketamine and its enantiomers

Effects of (R,S)-ketamine and its enantiomers on cognition in healthy subjects

Effects of (R,S)-ketamine on cognitive impairment in patients with MDD or BD

Effects of ketamine enantiomers on PCP-induced cognitive deficits in rodents

Cognitive impairment in the prodromal state of psychosis and the potential of arketamine

Dysbiosis of gut microbiota and cognitive impairment of psychiatric disorders

Conclusion and future directions

Acknowledgements

Declarations

Conflict of interest

Unsere Produktempfehlungen

e.Med Interdisziplinär

Neuer Inhalt

e.Med Neurologie & Psychiatrie

e.Med Psychiatrie

Weitere Artikel der Ausgabe 7/2023

Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis

Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options

Antidepressant effects of prolonged intermittent theta-burst stimulation monotherapy at the bilateral dorsomedial prefrontal cortex for medication and standard transcranial magnetic stimulation-resistant major depression: a three arm, randomized, double blind, sham-controlled pilot study

Tübinger Training for Autism Spectrum Disorders (TüTASS): a structured group intervention on self-perception and social skills of children with autism spectrum disorder (ASD)

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia

Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: a mirror-image study

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Typ-2-Diabetes und Depression folgen oft aufeinander

Darf man die Behandlung eines Neonazis ablehnen?

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

Update Psychiatrie